4.6 Review

Changes in heart rate dynamics of patients with schizophrenia treated with risperidone

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pnpbp.2010.04.017

关键词

Heart rate variability; Risperidone; Schizophrenia; Sympathovagal balance

资金

  1. Ministry of Health, Welfare & Family Affairs, Republic of Korea [A090828]
  2. Seoul National University Bundang Hospital [11-2008-017]
  3. Novartis
  4. Janssen
  5. Eli Lilly
  6. Pfizer
  7. Sanofi-Aventis
  8. Otsuka
  9. AstraZeneca
  10. Organon
  11. GlaxoSmithKline
  12. Lundbeck
  13. Korea Health Promotion Institute [A090828] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

Neurocardiac dysregulation has been reported in schizophrenia. Indices of heart rate variability (HRV) are useful in assessing the status of cardiac autonomic regulation. We explored within-subject changes in HRV indices in acutely ill patients with schizophrenia treated with risperidone. Sixteen medication-naive or medication-free patients with DSM-IV schizophrenia completed electrocardiogram (ECG) assessments at baseline and after six weeks of treatment with risperidone. Indices of HRV were extracted from 5-min resting ECG recordings and compared to those obtained from control subjects matched for age and gender. Psychiatric and drug-induced extrapyramidal symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS) and the Drug-Induced Extrapyramidal Symptoms Scale (1DIEPSS). In comparison with matched controls, patients with acute schizophrenia showed lower values of time-domain measures, lower high-frequency power (HF) and a higher ratio of low to high frequency (LF/HF). In the within-subject analyses, a significant decrease in LF/HF was associated with risperidone treatment. In addition, LF/HF, which initially co-clustered with clinical variables, congregated with other HRV measures after the six-week risperidone treatment. These results indicate that, in the therapeutic process, risperidone treatment may exert a beneficial influence on the sympathovagal imbalance in acute schizophrenia. (C) 2010 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据